Justin Martello, MD
Neurology · Newark, DENPI 1255622676
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $352,172 of the $485,271 with a category attached, or 72.6%. 30 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 29.3% of the total. 2025 is the largest year on record at $163,527, 2.2 times the $75,580 reported in 2019. Among neurology clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 759 payments — averaging $639.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$142K
- AbbVie$99K
- Acadia Pharmaceuticals Inc$84K
- Neurocrine Biosciences, Inc.$54K
- Acorda Therapeutics, Inc$29K
- Lundbeck LLC$23K
- plus $54K from 24 others
Across 45 payments — averaging $4333.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$98K
- Amneal Pharmaceuticals LLC$53K
- AbbVie$36K
- UCB SA$7K
- H. Lundbeck A S$2K
What the payments were for
- Consulting fees$58,73812%
- Speaking & faculty fees$352,17273%
- Travel & lodging$48,82410%
- Food & beverage$18,2814%
- Education$7,2561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 138 | $142,106 |
| AbbVie(2 entities) | 180 | $98,869 |
| Acadia Pharmaceuticals Inc | 108 | $83,829 |
| Neurocrine Biosciences, Inc. | 86 | $54,020 |
| Acorda Therapeutics, Inc | 35 | $28,685 |
| Lundbeck LLC | 31 | $23,494 |
| Amneal Pharmaceuticals LLC | 37 | $20,118 |
| MDD US Operations, LLC | 27 | $14,672 |
| Kyowa Kirin, Inc. | 9 | $5,732 |
| Insightec,inc | 37 | $4,793 |
| Boston Scientific | 14 | $2,628 |
| Avion Pharmaceuticals | 1 | $1,460 |
| Sunovion Pharmaceuticals Inc. | 9 | $1,371 |
| Abbott | 12 | $1,180 |
| Medtronic(2 entities) | 11 | $955 |
| UCB, Inc. | 3 | $504 |
| Merz North America, Inc. | 3 | $226 |
| Dr.reddy's Laboratories,inc. | 1 | $179 |
| Merz Pharmaceuticals, LLC | 2 | $86 |
| Jazz Pharmaceuticals Inc. | 3 | $81 |
| Adamas Pharmaceuticals, Inc. | 2 | $67 |
| Supernus Pharmaceuticals, Inc. | 2 | $56 |
| Neurelis, Inc. | 1 | $35 |
| AstraZeneca | 1 | $24 |
| Livanova USA, Inc. | 1 | $23 |
| CSL Behring | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Amgen | 1 | $14 |
| Cala Health, Inc. | 1 | $13 |
| Akcea Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$485,271 in reported general payments places this provider in the 95th percentile of 61 neurology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 78 | $420,118 |
| RytaryCarbidopa/Levodopa | 229 | $354,254 |
| GocovriAmantadine Hcl | 94 | $308,198 |
| Austedo XrDeutetrabenazine | 48 | $263,918 |
| Droxidopa | 57 | $163,423 |
| IngrezzaValbenazine Tosylate | 13 | $109,161 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 768 | $45,613 |
| NeuproRotigotine | 35 | $36,516 |
| OngentysOpicapone | 38 | $31,943 |
| CrexontCarbidopa/Levodopa | 27 | $22,546 |
| AmantadineAmantadine Hcl | 194 | $12,716 |
| RivastigmineRivastigmine Tartrate | 156 | $11,517 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 68 | $8,979 |
| Propranolol Hcl | 141 | $7,881 |
| Entacapone | 35 | $7,851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $83,829 | $420,11878 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $20,118 | $376,801256 claims |
| MDD US Operations, LLCGocovri | $14,672 | $308,19894 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $142,106 | $263,91848 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $54,020 | $141,10451 claims |
| UCB, Inc.Neupro | $504 | $36,51635 claims |
| Dr.reddy's Laboratories,inc.Pregabalin | $179 | $2,56167 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 61 neurology providers in Delaware.
Other neurology in Newark
- Jason SilversteenNewark$202K
- Etsegenet TizazuNewark$15K
- William SommersNewark$14K
- Lee DresserNewark$12K
- John PollardNewark$7K
- Shilpa KautaNewark$7K
- Brian OommenNewark$2K
- Huijun WangNewark$1K
- Muhammad AfzalNewark$1K
- Sandeep DevarapalliNewark$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.